Treatment for Alzheimer disease by CpG with RVG

2015 Fiscal Year Final Research Report

• Project/Area Number: 26670441
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Neurology
• Research Institution: Nagoya University
• Principal Investigator: Mizuno Tetsuya 名古屋大学, 環境医学研究所, 客員准教授 (70335008)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: ミクログリア / アルツハイマー病 / 機能性ペプチド核酸

Outline of Final Research Achievements

Soluble oligomeric amyloid beta (oAb) 1-42 causes synaptic dysfunction and neuronal injury in Alzheimer’s disease (AD). Microglia are involved in AD pathology. Microglia activated with unmethylated DNA CpG motif (CpG), a ligand for toll-like receptor 9, attenuated oAb neurotoxicity. In this study, we developed CpG with a specific target peptide for the brains; ravies virus glycoprotein (RVG). Intraperitoneal (IP) administration of CpG with RVG ameliorated the impairment of associative learning in APP/PS1 mouse model of AD. We propose that CpG with RVG may be an effective therapeutic strategy for inhibiting oAbeta 1-42 neurotoxicity in AD.

Free Research Field

神経内科